10x Genomics (TXG) Change in Receivables (2018 - 2025)
Historic Change in Receivables for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to -$93.5 million.
- 10x Genomics' Change in Receivables fell 224009.15% to -$93.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$41.3 million, marking a year-over-year decrease of 5329.3%. This contributed to the annual value of -$41.3 million for FY2025, which is 5329.3% down from last year.
- According to the latest figures from Q4 2025, 10x Genomics' Change in Receivables is -$93.5 million, which was down 224009.15% from -$16.3 million recorded in Q3 2025.
- 10x Genomics' Change in Receivables' 5-year high stood at $103.8 million during Q2 2025, with a 5-year trough of -$93.5 million in Q4 2025.
- Moreover, its 5-year median value for Change in Receivables was $3.0 million (2021), whereas its average is -$233150.0.
- Over the last 5 years, 10x Genomics' Change in Receivables had its largest YoY gain of 8518934.43% in 2025, and its largest YoY loss of 224009.15% in 2025.
- 10x Genomics' Change in Receivables (Quarter) stood at $6.8 million in 2021, then soared by 202.14% to $20.6 million in 2022, then tumbled by 46.78% to $11.0 million in 2023, then crashed by 60.18% to $4.4 million in 2024, then plummeted by 2240.09% to -$93.5 million in 2025.
- Its last three reported values are -$93.5 million in Q4 2025, -$16.3 million for Q3 2025, and $103.8 million during Q2 2025.